[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.202.12. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
May 11, 1994

A Word of Caution Regarding a New Long-Acting Bronchodilator

Author Affiliations

From the Office of the President, Medical College of Ohio, Toledo.

JAMA. 1994;271(18):1447-1448. doi:10.1001/jama.1994.03510420079038
Abstract

Physicians in the United States will soon be provided with a new, selective, long-acting β2-adrenergic aerosol, salmeterol xinafoate,1,2 for the treatment of asthma. In this issue of THE JOURNAL, D'Alonzo et al3 show that salmeterol inhaled twice daily compared with albuterol inhaled four times daily provides more effective bronchodilation in patients requiring maintenance therapy. Additionally, there was no deterioration in asthma control with the use of salmeterol throughout a 3-month period. Other studies have reported similar results.4

First Page Preview View Large
First page PDF preview
First page PDF preview
×